WellMedr Tirzepatide Review: Cost, the $99 Headline & Honest Verdict (2026)

WellMedr gets the hardest part of compounded tirzepatide pricing right and the easiest part wrong. The tirzepatide plan card states, in the company's own words, "Same price regardless of dosage" — titrate from 2.5 mg up to a therapeutic dose and the bill does not move, which is the charge most programs in this category quietly add between month two and month five. What it will not tell you is what that price is. The card advertises "Starting At $99 a month", the site banner sells its low rates as twelve-month lock-ins, and no standing month-to-month figure appears anywhere on the site. This review covers what WellMedr dispenses, what is actually published about cost, who actually fills the prescription, and the one claim on its microdose page that should stop you. Every fact here comes from the company's own published pages.

What WellMedr is

WellMedr is an online weight-care program selling compounded tirzepatide and compounded semaglutide, a brand pathway (Zepbound and Ozempic), and a separate eight-SKU microdose line that pairs a GLP-1 with NAD+, B12, methionine, inositol or L-carnitine — four oral, four injectable. Weight loss sits beside hair, testosterone and sexual-health programs on the same account.

Both halves of the supply chain are named, which is the part of this write-up that surprised us. The telehealth consent identifies the treating group as OpenLoop Health, Inc. and its state professional corporations, rather than referring vaguely to "a licensed provider in your state." And WellMedr names its compounding pharmacy: its privacy policy identifies Mycelium Pharmacy as "our U.S.-licensed fulfillment pharmacy", and repeats the pairing in a Partners block — "Medical Provider Network: OpenLoop Health · Fulfillment Pharmacy Partner: Mycelium Pharmacy." On a compounded product, whose quality rests entirely on who mixes it, that is the disclosure that matters most, and it is a facility you can look up before you buy. One caveat: nothing on the site states whether that pharmacy is a state-licensed 503A or an FDA-registered 503B outsourcing facility, so the regime it is inspected under stays unstated.

You complete an online intake, a clinician reviews it, and the compounded plan ships every four weeks.

Hold on to that shipping cadence, because it is a pricing fact wearing a logistics costume. Every four weeks is 13 shipments a year, not 12 — so an advertised "per month" figure understates the annual cost by about 8.6% before any other consideration.

What WellMedr costs in 2026

The tirzepatide card says "Starting At $99 a month." Two words in that sentence are doing the work. "Starting At" is one; the other is "month," which as above means four weeks.

The $99 is a discounted figure, and the site says so in three places at once. A banner across the top of every page reads: "🎉 Lock In $200 OFF Every Month, or $59/mo on 12/month Plans — For Life." Further down, a "New Customer Offer: $150 off for Life" appears. The lowest advertised rate on the site — the $59 semaglutide figure — is explicitly tied to a twelve-month plan in the banner's own words. The plan card meanwhile promises "Cancel or change anytime." Those two statements can both be true only if the low number and the cancel-anytime term belong to different plans, and the site never reconciles them.

No standing month-to-month price for compounded tirzepatide is published anywhere. We checked the route a buyer would take: both "Check Eligibility" buttons hand off to intake.wellmedr.com, a checkout app that will not load without a plan parameter, and its own weight-loss product page prints "Month-to-month plan" with no figure beside it at all. So the number you will actually be billed is not readable before the medical intake. That is the finding — not a rate we can quote and you can check.

The brand prices are published, and they are startling. Brand Zepbound is listed "starting at $1,599" and brand Ozempic at "$1,399", each on a "Month-to-month plan" that includes clinician oversight and coaching. For scale: buying Zepbound directly from the manufacturer's self-pay route runs $299 at 2.5 mg, $399 at 5 mg and $449 at 7.5 mg and above (28-day supply, prices in effect since December 1, 2025). Even crediting the bundled clinical care, that is a very large gap, and anyone considering the brand route through WellMedr should price the direct one first — see our Zepbound cost and savings guide and our best place to get Zepbound online roundup.

The microdose line publishes almost nothing. Eight SKUs, two prices: an injectable tirzepatide-plus-NAD+-and-B12 formulation and a tirzepatide-plus-B12-methionine-inositol one, both $199/month. The other six print no figure. The product records behind all eight return a zero-dollar placeholder rather than a price, which is a post-intake artifact and not an offer of anything free.

The compounded-vs-brand question

The compounded plans are the cheap ones, and WellMedr is unusually direct about what that means. Its Required Safety Notice sits on the pricing page itself, not in a footer: "Compounded medications are regulated by state Boards of Pharmacy, but are not evaluated by the FDA for safety or efficacy." The same notice spells out the risk of thyroid C-cell tumors, including thyroid cancer and medullary thyroid carcinoma (MTC), and tells readers to seek immediate care for neck swelling, hoarseness, trouble swallowing or shortness of breath. Putting that where the buying decision happens is a real credit, and it deserves saying before the criticism that follows.

The distinction it is disclosing:

• •Brand tirzepatide is Eli Lilly's FDA-approved Zepbound (weight management, obstructive sleep apnea) and Mounjaro (type 2 diabetes) — the exact product studied in the pivotal trials.
• •Compounded tirzepatide is pharmacy-made, not FDA-approved, and was not the product tested in those trials.

One further piece of wording to read carefully: the top of the site advertises "FDA-regulated pharmacies." That is a claim about the facility, not the medicine. It does not make a compounded product FDA-approved, and the company's own safety notice says as much. Our guide to whether compounded tirzepatide is still legal in 2026 covers where the regulatory line now sits.

Two things about the compounded route here are genuinely checkable, and both took a fetch rather than a glance. The pharmacy is named — Mycelium Pharmacy, in the privacy policy — so you can research the facility that will actually fill the prescription. And the LegitScript certification seal on the pricing page is served directly from LegitScript's own CDN rather than being a lookalike image the company hosts itself — the check we run on every badge of this kind, and one that providers we review here do sometimes fail (our trust index records the results).

The claim that should stop you

The microdosing page headlines "ZERO Side Effects", subheaded "Zero side effct for 70%+ of members" — their spelling, not ours. Read it twice, because the two halves contradict each other: a rate of "70%+ of members" is not zero, and a compounded GLP-1 that the company's own Required Safety Notice attaches thyroid C-cell tumor warnings to is not a medication anyone can promise zero side effects from. Nausea, vomiting, diarrhea and constipation are the ordinary experience of starting a GLP-1, and the labeled risks include acute pancreatitis and gallbladder disease. Whatever the intent, an unqualified zero-side-effect headline over a prescription product is the single most notable thing on this site, and it sits on the page aimed at the readers least likely to push back on it.

The marketing around it wants the same skepticism. Celebrity endorsements run the length of the home page, "used by 1,000,000+ patients" sits beside before-and-after testimonials, and those testimonials carry their own disclosure: "Inspired by real patient success stories in similar Telehealth programs." In other words they are not WellMedr patients. The disclosure is there, which is to the company's credit; what it discloses is that the social proof is not evidence about this program.

Whatever you decide, get your exact quote in writing before you start, and read the labeled risks first — tirzepatide carries warnings for acute pancreatitis, gallbladder disease, and a boxed thyroid C-cell tumor warning. See our guides on Zepbound side effects, the gallbladder risk, and the thyroid cancer warning.

Does the drug work? (Separate from the provider)

Judge the provider on price, oversight and disclosure; judge the molecule on its trials. Tirzepatide's are strong — roughly 15–21% of body weight over 72 weeks in SURMOUNT-1¹, and better than semaglutide head-to-head² — but they were run on the brand drug at FDA-approved doses. Our tirzepatide evidence guide has the full picture.

The honest verdict

"Same price regardless of dosage" is a genuinely good term, and WellMedr prints it on the tirzepatide card rather than burying it. Add a named clinical group, a named compounding pharmacy, a brand pathway alongside the compounded one, and a safety notice placed where the buying decision happens, and the bones of a serious program are there.

But you cannot price this program from the outside. The $99 is a "starting at" figure with up to three discounts stacked behind it, the site's own lowest rate is tied to a twelve-month plan while the card promises cancel-anytime, a "month" is four weeks, and no standing month-to-month rate is published on any page. Add the "ZERO Side Effects" headline and this is a service you should only enter with a written quote and clear eyes.

If what you want is a number you can read before you start an intake, System Labs states a flat $179/month at every dose in its own FAQ, and CoreAge Rx publishes its rate up front. Compare the whole field in our best tirzepatide providers ranking, and see cheapest tirzepatide for where a real $99 would land if it were one.